326 related articles for article (PubMed ID: 19705280)
1. Mesalamine protects against colorectal cancer in inflammatory bowel disease.
Tang J; Sharif O; Pai C; Silverman AL
Dig Dis Sci; 2010 Jun; 55(6):1696-703. PubMed ID: 19705280
[TBL] [Abstract][Full Text] [Related]
2. 5-Aminosalicylate use and colorectal cancer risk in inflammatory bowel disease: a large epidemiological study.
van Staa TP; Card T; Logan RF; Leufkens HG
Gut; 2005 Nov; 54(11):1573-8. PubMed ID: 15994215
[TBL] [Abstract][Full Text] [Related]
3. 5-aminosalicylate is not chemoprophylactic for colorectal cancer in IBD: a population based study.
Bernstein CN; Nugent Z; Blanchard JF
Am J Gastroenterol; 2011 Apr; 106(4):731-6. PubMed ID: 21407180
[TBL] [Abstract][Full Text] [Related]
4. Chemopreventive effects of 5-aminosalicylic acid on inflammatory bowel disease-associated colorectal cancer and dysplasia: a systematic review with meta-analysis.
Qiu X; Ma J; Wang K; Zhang H
Oncotarget; 2017 Jan; 8(1):1031-1045. PubMed ID: 27906680
[TBL] [Abstract][Full Text] [Related]
5. 5-Aminosalicylic acid therapy and the risk of colorectal cancer among patients with inflammatory bowel disease.
Terdiman JP; Steinbuch M; Blumentals WA; Ullman TA; Rubin DT
Inflamm Bowel Dis; 2007 Apr; 13(4):367-71. PubMed ID: 17206695
[TBL] [Abstract][Full Text] [Related]
6. Patients' knowledge and fear of colorectal cancer risk in inflammatory bowel disease.
Lopez A; Collet-Fenetrier B; Belle A; Peyrin-Biroulet L
J Dig Dis; 2016 Jun; 17(6):383-91. PubMed ID: 27129893
[TBL] [Abstract][Full Text] [Related]
7. Cancer risk and chemoprevention in Chinese inflammatory bowel disease patients: a population-based cohort study.
Mak JWY; So J; Tang W; Yip TCF; Leung WK; Li M; Lo FH; Ng KM; Sze SF; Leung CM; Tsang SWC; Shan EHS; Chan KH; Lam BCY; Hui AJ; Chow WH; Chan FKL; Ng SC
Scand J Gastroenterol; 2020 Mar; 55(3):279-286. PubMed ID: 32119788
[No Abstract] [Full Text] [Related]
8. The effects of aminosalicylates or thiopurines on the risk of colorectal cancer in inflammatory bowel disease.
Carrat F; Seksik P; Colombel JF; Peyrin-Biroulet L; Beaugerie L;
Aliment Pharmacol Ther; 2017 Feb; 45(4):533-541. PubMed ID: 27995656
[TBL] [Abstract][Full Text] [Related]
9. Chemoprophylaxis of colorectal cancer in inflammatory bowel disease: current concepts.
Levine JS; Burakoff R
Inflamm Bowel Dis; 2007 Oct; 13(10):1293-8. PubMed ID: 17567870
[TBL] [Abstract][Full Text] [Related]
10. Aminosalicylates and colorectal cancer in IBD: a not-so bitter pill to swallow.
Ryan BM; Russel MG; Langholz E; Stockbrugger RW
Am J Gastroenterol; 2003 Aug; 98(8):1682-7. PubMed ID: 12907319
[TBL] [Abstract][Full Text] [Related]
11. Risk of colorectal cancer in self-reported inflammatory bowel disease and modification of risk by statin and NSAID use.
Samadder NJ; Mukherjee B; Huang SC; Ahn J; Rennert HS; Greenson JK; Rennert G; Gruber SB
Cancer; 2011 Apr; 117(8):1640-8. PubMed ID: 21472711
[TBL] [Abstract][Full Text] [Related]
12. Chemoprevention for colon cancer: new opportunities, fact or fiction?
Terhaar Sive Droste JS; Tuynman JB; Van Dullemen HM; Mulder CJ
Scand J Gastroenterol Suppl; 2006; (243):158-64. PubMed ID: 16782636
[TBL] [Abstract][Full Text] [Related]
13. Does aspirin or non-aspirin non-steroidal anti-inflammatory drug use prevent colorectal cancer in inflammatory bowel disease?
Burr NE; Hull MA; Subramanian V
World J Gastroenterol; 2016 Apr; 22(13):3679-86. PubMed ID: 27053860
[TBL] [Abstract][Full Text] [Related]
14. Inflammation and disease duration have a cumulative effect on the risk of dysplasia and carcinoma in IBD: a case-control observational study based on registry data.
Nieminen U; Jussila A; Nordling S; Mustonen H; Färkkilä MA
Int J Cancer; 2014 Jan; 134(1):189-96. PubMed ID: 23797639
[TBL] [Abstract][Full Text] [Related]
15. Colorectal cancer in inflammatory bowel disease: the risk, pathogenesis, prevention and diagnosis.
Kim ER; Chang DK
World J Gastroenterol; 2014 Aug; 20(29):9872-81. PubMed ID: 25110418
[TBL] [Abstract][Full Text] [Related]
16. [Chemoprevention of colorectal cancer in inflammatory bowel disease].
Han SH; Lee J
Korean J Gastroenterol; 2014 Jan; 63(1):3-10. PubMed ID: 24463282
[TBL] [Abstract][Full Text] [Related]
17. Does the use of 5-aminosalicylates in inflammatory bowel disease prevent the development of colorectal cancer?
Bernstein CN; Blanchard JF; Metge C; Yogendran M
Am J Gastroenterol; 2003 Dec; 98(12):2784-8. PubMed ID: 14687833
[TBL] [Abstract][Full Text] [Related]
18. Role of 5-aminosalicylate in preventing colorectal cancer.
Riyaz S; Hamlin J; Everett S
Am J Gastroenterol; 2011 Sep; 106(9):1720-1; author reply 1721-2. PubMed ID: 21897414
[No Abstract] [Full Text] [Related]
19. Chemoprevention: risk reduction with medical therapy of inflammatory bowel disease.
Chan EP; Lichtenstein GR
Gastroenterol Clin North Am; 2006 Sep; 35(3):675-712. PubMed ID: 16952746
[TBL] [Abstract][Full Text] [Related]
20. Chemoprevention of colorectal cancer in ulcerative colitis.
Croog VJ; Ullman TA; Itzkowitz SH
Int J Colorectal Dis; 2003 Sep; 18(5):392-400. PubMed ID: 12904996
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
